In fact, similar to our findings, pharmacologic targeting of B-Raf results in increased activity of c-Raf and a paradoxical increase in ERK phosphorylation and tumorigenesis in KRas-mutant cancers [53,56–58]; though this is not the case with genetic deletion of B-Raf. The gene discussed is RAF1; the disease is cancer.